First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic programs and project advancements in our Annual Report 2016.

More Info

Hematological cancers 
affect adults and children alike.

MorphoSys is developing several blood cancer programs.

More Info

Solid tumors can occur in 
several organs of the human body.

MorphoSys and its partners are working on a broad portfolio of new therapies.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

17/05/2018
Annual General Meeting of MorphoSys AG Elects New Supervisory Board Members
17/05/2018
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood...
02/05/2018
MorphoSys AG Reports First Quarter 2018 Results
01/05/2018
MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical...
26/04/2018
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea
23/04/2018
MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and...
18/04/2018
MorphoSys Announces Pricing of Initial Public Offering of American...
18/04/2018
Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of...
10/04/2018
MorphoSys Nominates New Candidates for Supervisory Board
09/04/2018
Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS)...

May 21, 2018
UBS Global Healthcare Conference
New York, NY, US

conferences

 

 

 

 

Simon Moroney, CEO
on Strategy and Goals